Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Perioperative Opdivo alone, in combination with Yervoy safe in patients with HCC
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients | Journal for ImmunoTherapy of Cancer
Combining Nivolumab & Ipilimumab Improved Overall Survival in Melanoma | Article | NursingCenter
![PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/23dbeed54cde655fb6a12697b02c9ff303515da7/11-Table2-1.png "PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar")
PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | NEJM
References in Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial - The Lancet Oncology
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Evolving impact of long-term survival results on metastatic melanoma treatment | Journal for ImmunoTherapy of Cancer
Nivolumab Combined with Ipilimumab
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post
Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors | medRxiv
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | NEJM
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
NEJM on Twitter: "Original Article: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/0pcpqYVD59 https://t.co/Gheb94m7pa" / Twitter
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
